登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioRxiv，3月14日，Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-15

  • Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route

    Wei Deng, Linlin Bao, Hong Gao, Zhiguang Xiang, Yajin Qu, Zhiqi Song, Shuran Gong, Jiayi Liu, Jiangning Liu, Pin Yu, Feifei Qi, Yanfeng Xu, Fengli Li, Chong Xiao, Qi Lv, Jing Xue, Qiang Wei, Mingya Liu, Guanpeng Wang, Shunyi Wang, Haisheng Yu, Xing Liu, Wenjie Zhao, Yunlin Han, Chuan Qin

    doi: https://doi.org/10.1101/2020.03.13.990036

    Abstract

    The outbreak of Corona Virus Disease 2019 (COVID-19) is highly infectious and transmitted mainly through human-to-human transmission via respiratory droplets and direct or close contact to the patients with SARS-CoV-2. The other potential transmission routes remain to be further researched. In some clinical cases, samples of tears and conjunctival secretions from both SARS-CoV and SARS-CoV-2 patients with conjunctivitis displayed detectable viral RNA. A previous study reported the case of a clinician who was infected with SARS-CoV-2 while working with patients under all safeguards except eye protection.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.03.13.990036v1
119浏览量
原文链接
相关报告

  • 《BioRxiv，3月14日，Reinfection could not occur in SARS-CoV-2 infected rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-15
    • Reinfection could not occur in SARS-CoV-2 infected rhesus macaques Linlin Bao, Wei Deng, Hong Gao, Chong Xiao, Jiayi Liu, Jing Xue, Qi Lv, Jiangning Liu, Pin Yu, Yanfeng Xu, Feifei Qi, Yajin Qu, Fengdi Li, Zhiguang Xiang, Haisheng Yu, Shuran Gong, Mingya Liu, Guanpeng Wang, Shunyi Wang, Zhiqi Song, Wenjie Zhao, Yunlin Han, Linna Zhao, Xing Liu, Qiang Wei, Chuan Qin doi: https://doi.org/10.1101/2020.03.13.990226 Abstract An outbreak of the Corona Virus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome CoV-2 (SARS-CoV-2), began in Wuhan and spread globally. Recently, it has been reported that discharged patients in China and elsewhere were testing positive after recovering. However, it remains unclear whether the convalescing patients have a risk of "relapse" or "reinfection". The longitudinal tracking of re-exposure after the disappeared symptoms of the SARS-CoV-2-infected monkeys was performed in this study. We found that weight loss in some monkeys, viral replication mainly in nose, pharynx, lung and gut, as well as moderate interstitial pneumonia at 7 days post-infection (dpi) were clearly observed in rhesus monkeys after the primary infection. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    111浏览量
    原文链接

  • 《Nature，6月9日，Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-10
    • Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Brandi N. Williamson, Friederike Feldmann, Benjamin Schwarz, Kimberly Meade-White, Danielle P. Porter, Jonathan Schulz, Neeltje van Doremalen, Ian Leighton, Claude Kwe Yinda, Lizzette Pérez-Pérez, Atsushi Okumura, Jamie Lovaglio, Patrick W. Hanley, Greg Saturday, Catharine M. Bosio, Sarah Anzick, Kent Barbian, Tomas Cihlar, Craig Martens, Dana P. Scott, Vincent J. Munster & Emmie de Wit Nature (2020) Abstract Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection9. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages 12hrs after the first treatment administration. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment.
    60浏览量
    原文链接